Thanks to everyone for all of their great questions and converstions on this site.
Check my bio for background. 2 months into ADT therapy after diagnosis in January. I am starting docetaxyl chemo via an NIH trial in May. M9241 - ncbi.nlm.nih.gov/pmc/articl.... We are hopeful for both good chemo results as well as a positive response for the immunotherapy. This trial stage is mostly to test feasability or delivering immunotherapy along with chemotherapy.
Is anyone familiar with, or perhaps a patient, of this study that can share any thoughts?
Written by
4tunate1
To view profiles and participate in discussions please or .
Great strategy and also actions plan. Thank you for sharing
Conclusions: M9241 was found to be safe and well tolerated in PCa pts. PSA declines occurred in 5 of 8 evaluable pts. As with the phase 1 study, increases in NK subpopulations were seen in the small number of evaluable pts. These preliminary findings of a necrosis-targeting immunocytokine will be evaluated further in combination studies with cytotoxic therapy. M9241 is currently being evaluated in combination with docetaxel in metastatic prostate cancer (NCT04633252).
Important notes I would consider is work with MO for all side effects seriously. Write down all side effects and share list with MO and make sure to make progress on it.
Just diagnosed in Jan 2024. started ADT therapy in February first with degarelix shots in the belly and oral abiraterone/prednisone. Got first Lupron shot in March. Still taking abiraterone/prednisone daily. Xtandi has not been part of my therapy.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.